Novartis Focalin XR Extended-Release ADHD Therapy Will Launch In June
This article was originally published in The Pink Sheet Daily
Executive Summary
The May 26 Focalin XR approval marks Novartis’ first ADHD treatment indication in adults. The NDA was supported by two clinical trials, one in adults and one in children.